Genentech, a member of the Roche Group, is a leading player in the pharmaceutical preparation manufacturing industry, headquartered in South San Francisco, US. Founded in 1976, the company has pioneered advancements in biotechnology, focusing on the development of innovative medicines for serious medical conditions, particularly in oncology, immunology, and neuroscience.
With a strong commitment to research and development, Genentech has introduced several groundbreaking therapies, including targeted treatments that have transformed patient care. Its unique approach to drug development, emphasising personalised medicine, has solidified its position as a market leader. Notable achievements include being one of the first biotechnology companies to successfully bring a monoclonal antibody to market, setting a benchmark for the industry. Genentech continues to drive progress in healthcare, making significant contributions to the global pharmaceutical landscape.
+5 vs industry average
Genentech’s score of 43 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Genentech?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
Scope 3 accounts for ••• of total emissions.
Genentech's reported carbon emissions
Genentech, a US-based pharmaceutical preparation manufacturer, has reported significant greenhouse gas emissions across its operations. **2019 Emissions:** Genentech's total reported emissions for 2019 were approximately 190,000,000 kg CO2e. This total encompasses: * **Scope 1:** Approximately 80,000,000 kg CO2e, primarily from stationary combustion (about 61,780,000 kg CO2e), mobile combustion, and fugitive emissions. * **Scope 2:** Approximately 63,000,000 kg CO2e, based on location-based reporting for purchased electricity. * **Scope 3:** Approximately 73,000,000 kg CO2e, with business travel and employee commute being significant contributors. Notably, purchased goods and services were a missing data point for this scope. **Reduction Targets and Initiatives:** Genentech has set a near-term reduction target to achieve a 30% absolute reduction in CO2 emissions from its onsite energy use by 2020, compared to 2010 levels. **Data Cascading Information:** As a current subsidiary of Roche Holding AG, Genentech's SBTi reduction targets are cascaded from its corporate family. The primary sources for its performance data originate from Genentech, Inc. itself.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Genentech’s Climate Goals (2030 & 2050)
1 goal2020
30% reduction in all scopes
We're targeting a 30% absolute reduction in CO2 emissions from our onsite energy use, compared to 2010 levels.
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 1 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
2 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Emissions comparison with industry peers
View similar organisations
Genentech
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project